Skip to main content
OpenTrials
Completed

NCT Number: NCT05403762

Prevention of Incontinence-associated Dermatitis

Incontinence-associated dermatitis (IAD) is an inflammation of the skin caused by prolonged direct contact of the skin with urine and/or stool. Elderly and care-dependent people are often affected by this type of inflammation. Gentle skin cleansing and the use of skin protection products are recommended. Available skin protection products can be categorized into film-forming or lipophilic skin protectants depending on the ingredients and overall composition. There is no evidence about the superiority of one product compared to another regarding skin protection. The overall aim of this study is to compare the effects of two skin protection products compared to an untreated control group. An exploratory trial in elderly nursing home residents and geriatric patients will be conducted.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Incontinence-associated Dermatitis Erythema Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Charité Universitätsmedizin Berlin

Berlin, State of Berlin, 10117, Germany

About this study

Incontinence-associated dermatitis (IAD) is an inflammation of the skin caused by prolonged and direct contact of the skin with urine and/or stool. It may occur in all age groups but elderly and care-dependent incontinent people are often affected by this type of inflammation. Promotion of continence, use of absorbent products and structured skin care are recommended to prevent and/or treat IAD. Available skin protection products can be categorized into film-forming or lipophilic skin protectants depending on the ingredients and overall composition. Currently, there is no evidence about the superiority of one product compared to another regarding skin protection. The overall aim of this study is to compare the effects of two skin protection products compared to an untreated control group. An exploratory randomized controlled trial in incontinent elderly nursing home residents and geriatric patients will be conducted. In the two intervention groups, a film-forming or a lipophilic skin protection product will be applied in addition to standardized skin care regimens. Every other day, investigators will perform skin inspections, including instrumental skin measurements to quantify erythema for a total study period of n= 14 days. IAD- related pain and itch will be assessed. A total of n= 210 nursing home residents and geriatric patients in Berlin, Germany, aged over 65 years, who are affected by urinary and faecal incontinence without signs of severe IAD will be included.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Geriatric patients or residents being incontinent of urine and stool
  • Expected minimum length of stay of 14 days at the care facility
  • Intact skin with no clinical signs of IAD OR
  • intact skin with early clinical signs of IAD (IAD category 1A)
  • Written informed consent

Exclusion criteria

  • Residents/patients at the end of life
  • Residents/Patients with IAD category 1B, 2A, 2B and/or signs of clinical infection in the IAD area
  • Any skin condition or wounds (at investigational areas of the skin) requiring additional treatment (e. g. pressure ulcers, intertrigo, infection)
  • Known hypersensitivity or allergy to silicones and/or topical leave-on products
  • Topical treatments in the IAD area.

Treatment and study plan

ESENTA™ Skin Barrier Spray (ConvaTec, UK)

Other

The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.

Other names: Film-forming skin protectant

Hydrophobes Basisgel DAC

Other

The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.

Other names: Hydrophobic skin protectant

Primary outcomes

  1. Incidence of Incontinence-associated Dermatitis (IAD)

    Time frame: 14 Days

    Number of subjects developing IAD of all subjects (cumulative incidence).

    Classification of IAD according to Ghent Global IAD Categorisation Tool (GLOBIAD) (Category 1A, 1B, 2A, 2B). The GLOBIAD categorises IAD severity based on visual inspection of the affected skin areas.

    Category 1A: Persistent redness without clinical signs of infection Category 1B: Persistent redness with clinical signs of infection Category 2A: Skin loss without clinical signs of infection Category 2B: Skin loss with clinical signs of infection

Secondary outcomes

  1. Erythema (Instrumental Measurement)

    Time frame: 14 Days

    Erythema measured with the Mexameter MX® 18 (Courage + Khazaka, Cologne, Germany). Means of two duplicate measurements per skin area are displayed in arbitrary units (AU) ranging from 0 (= no erythema) to 999 (= extreme erythema).

  2. Erythema (Visual Inspection)

    Time frame: 14 Days

    Clinical rating of erythema is conducted according to the item 'Redness' of the incontinence-associated dermatitis and its severity (IADS) instrument. The 3-Item-Scale describes 'Redness' as (1) none, (2) pink, (3) red/ bright red.

  3. Incidence of Erosion

    Time frame: 14 Days

    The presence (no or yes) of erosion is defined according to the latest International League of Dermatological Societies glossary of cutaneous lesions as a loss of either a portion of or the entire epidermis. Number of subjects developing erosions of all subjects (cumulative incidence).

  4. Incidence of Maceration

    Time frame: 14 Days

    The presence (no or yes) of maceration is defined as the result of prolonged exposure (of the skin) to moisture and causes the skin to soften and breakdown so that the connective fibres can be teased apart and the skin often exhibits a white appearance. Number of subjects developing maceration of all subjects (cumulative incidence).

  5. IAD Related Pain

    Time frame: 14 Days

    Numeric Rating Scale (NRS) pain score. The NRS ranges from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain severity. The NRS was administered only to participants without cognitive impairment (MMSE ≥24).

  6. Incidence of IAD Related Itch

    Time frame: 14 Days

    IAD related itch will be reported directly by patients (yes or no). Number of subjects reporting itch of all subjects (cumulative incidence).

  7. Presence of Local Intolerances

    Time frame: 14 Days

    The presence of local intolerances will be assessed with the following options:

    (0) None;

    • homogeneous redness with scattered papules;
    • homogeneous redness and homogeneous infiltration
    • homogeneous redness and infiltration with vesicles
    • homogeneous redness and infiltration with coalescing vesicles

  8. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 14 Days

    AEs and SAEs will be documented and reported according to the current regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (MDR) Article 2.

  9. Incidents and Serious Incidents

    Time frame: 14 Days

    Incidents abd serious incidents will be documented according to the definition of the EU regulation 2017/745 MDR Article 2 and reported to the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Registry information

Official study title

Comparison of Two Skin Protection Regimes for the Prevention of Incontinence-associated Dermatitis in Geriatric Care: an Exploratory Trial (PID)

Acronym: PID

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jun 3, 2022
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.